NCT04298879View on ClinicalTrials.gov

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

July 27, 2021

Study Completion Date

November 21, 2023

Conditions
Indolent Non-hodgkin Lymphoma
Interventions
DRUG

IBI376

IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily

Trial Locations (1)

Unknown

Ruijin hospital, school of medicine, Shanghai jiao tong university, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04298879 - IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma | Biotech Hunter | Biotech Hunter